- Melanoma facts
- What is melanoma?
- What does melanoma look like? What are melanoma symptoms and signs?
- What if the skin changes are rapid or dramatic?
- What are the causes and risk factors for melanoma?
- How can people estimate their level of risk for melanoma?
- What are the types of melanoma?
- What tests do health care professionals use to diagnose melanoma?
- What are melanoma treatment options?
- How do doctors determine the staging and prognosis (outlook) of a melanoma?
- What is recurrent melanoma?
- What is metastatic melanoma?
- What are the signs of symptoms of metastatic melanoma?
- What are the treatments for metastatic melanoma?
- What are the survival rates for metastatic melanoma?
- What methods are available to help prevent melanoma?
- What research is being done on melanoma?
- Where can people get more information about melanoma?
- Melanoma is a cancer of melanocytes, cells that produce the pigment melanin. Most melanomas develop on the skin.
- It is not unusual for patients or their spouses to recognize cutaneous (skin) melanomas.
- Caught early, most melanomas can be cured with relatively minor surgery.
- Melanoma can be more serious than the other forms of skin cancer because it tends to spread (metastasize) to other parts of the body, causing serious illness and death.
- Spots suspicious for melanoma usually show one or more of the following symptoms and signs (the ABCDs):
- Border irregularity,
- Color changes or too many colors in one mole,
- Diameter more than 6 mm (the size of a pencil eraser).
- Some now add a fifth letter: E for Evolving, or changing over time.
- Elevated risk factors for melanoma include Caucasian (white) ancestry, fair skin, light hair and light-colored eyes, a history of intense sun exposure, close blood relatives with melanoma, and moles that are unusually numerous, large, irregular, or "funny looking."
- Malignant melanoma in situ refers to a very thin superficial spreading melanoma that does not extend more deeply than the outermost layers of skin.
- Doctors diagnose melanoma by performing a biopsy in which they remove a piece of skin for analysis. Whenever possible, it is best to remove the entire lesion in question.
- The most common forms of melanoma are superficial spreading melanoma, nodular melanoma, and lentigo maligna.
- Early treatment of localized melanoma is primarily by surgical removal.
- Changing or suspicious spots on the skin should be brought to medical attention right away.
- When it comes to spots on the skin, it is always better to be safe than sorry. Melanoma is a potentially serious form of skin cancer. Diagnosed early and treated properly, it can very often be cured with relatively minor surgery alone.
What is melanoma?
Melanoma is a cancer that develops in melanocytes, the pigment cells present in the skin. It can be more serious than the other forms of skin cancer because of a tendency to spread to other parts of the body (metastasize) and cause serious illness and death. About 50,000 new cases of melanoma are diagnosed in the United States every year.
Because most melanomas occur on the skin where they can be seen, patients or their spouses are often the first to detect suspicious tumors. Early detection and diagnosis are crucial. Caught early, most melanomas can be cured with relatively minor surgery.
This article is written from the standpoint of the patient. In other words, instead of describing the disease in exhaustive detail, the article focuses on answering the questions: "How do I know if I have melanoma?" and "Should I be checked for it?"
Spots on the skin
Guideline # 1: Nobody can conclusively diagnose him- or herself. If someone sees a spot that looks as though it is new or changing, he or she should show it to a doctor. When it comes to spots on the skin, it is always better to be safe than sorry.
Everybody gets spots on their skin. The older we are, the more spots we have. Most of these spots are benign. That means they are neither cancerous nor on the way to becoming cancerous. These may include freckles, benign moles, collections of blood vessels called cherry angiomas, or raised, irregular, pigmented bumps on the skin called seborrheic keratoses.
Guideline # 2: The vast majority of moles (melanocytic nevi) stay as moles and do not turn into anything else. Most melanomas do not arise in preexisting moles. For that reason, having all of one's moles removed to "prevent melanoma" does not make sense.
Some people are born with moles (the medical name is "nevus," plural "nevi"). Almost everyone develops them, starting in childhood. On average, people have about 25 moles, though some have fewer and others many more. Moles may be flat or raised, and they may range in color from tan to light brown to black. Moles may lose their color and end up flesh colored. It is unusual to develop new pigmented moles after age 35.
What does melanoma look like? What are melanoma symptoms and signs?
Guideline # 3: A changing spot may be a problem, but not every change means cancer. A mole may appear and then get bigger or become raised but still be only a mole. It is normal for many moles to start flat and dark, become raised and dark, and then later lose much of their color. This process takes many years.
Most public-health information about melanoma stresses the so-called ABCDEs:
- Asymmetry: One half of the mole is different from the other half.
- Border irregularity: The spot has borders which are not smooth and regular but uneven or notched.
- Color: The spot has several colors in an irregular pattern or is a very different color than the rest of one's moles.
- Diameter: The spot is larger than the size of a pencil eraser (6 mm).
- Evolving: The mole is changing in size, shape, color, or overall texture. This may also include new bleeding.
These guidelines are somewhat helpful, but the problem is that many normal moles and other benign lesions of the skin are not perfectly symmetrical in their shape or color. Many spots, which seem to have one or more of the ABCDEs, are in fact just ordinary moles and not melanomas. Additionally, some melanomas do not fit this description but may still be spotted by a primary care physician or dermatologist. Not all melanomas have color or are raised on the skin. Amelanotic melanomas have little or no color may be confused with traumatized benign nevi or basal cell carcinoma. Desmoplastic melanoma may appear to be a thickened area of skin like a scar. As a rule, melanoma is not painful unless traumatized. They sometimes itch, but this has no diagnostic or prognostic importance.
What if the skin changes are rapid or dramatic?
Guideline # 4: The more rapid and dramatic the change, the less serious the problem.
When changes such as pain, swelling, or even bleeding come on rapidly, within a day or two, they are likely to be caused by minor trauma, often a kind one doesn't remember (like scratching the spot while sleeping). If a spot changes rapidly and then goes back to the way it was within a couple of weeks, or falls off altogether, it is not likely to represent anything serious. Nevertheless, this would be a good time to say once again: Nobody can diagnose him- or herself. If one sees a spot that looks as though it is new or changing, show it to a doctor. If one see a spot that doesn't look like one's other spots, it should be evaluated.
What are the causes and risk factors for melanoma?
Guideline # 5: Individual sunburns do raise one's risk of melanoma. However, slow daily sun exposure, even without burning, may also substantially raise someone's risk of skin cancer.
Factors that raise one's risk for melanoma include the following:
- Caucasian (white) ancestry
- Fair skin, light hair, and light-colored eyes
- A history of intense, intermittent sun exposure, especially in childhood
- Many (more than 100) moles
- Large, irregular, or "funny looking" moles
- Close blood relatives -- parents, siblings, and children -- with melanoma
The presence of close (first-degree) family with melanoma is a high risk factor, although looking at all cases of melanoma, only 10% of cases run in families.
Having a history of other sun-induced skin cancers, such as the much more common basal cell or squamous cell carcinomas, indirectly raises one's risk of melanoma because they are markers of long-term sun exposure. The basic cell type is different, however, and a basal cell or squamous cell carcinoma cannot "turn into melanoma" or vice versa.
How can people estimate their level of risk for melanoma?
The best way to know one's risk level is to have a dermatologist perform a full body examination. That way one will find out whether the spots one has are moles and, if so, whether they are abnormal in the medical sense.
The medical term for such moles is atypical. This is a somewhat confusing term, because among other things the criteria for defining it are not clear, and it's not certain that an atypical mole is necessarily precancerous. Patients who have lots of "atypical moles" (more than 24) do have a higher risk for developing melanoma but not necessarily within one of their existing funny-looking moles. It may be a challenge to find the "baby melanoma" in the middle of a back full of large, dark, or irregular moles. If someone has such moles, a doctor will recommend regular surveillance and may recommend biopsy of the most unusual or worrisome looking moles.
Sometimes, one learns at a routine skin evaluation that one does not necessarily need annual routine checkups. In other situations, a doctor may recommend regular checks at 6-month or yearly intervals.
What are the types of melanoma?
The main types of melanoma are as follows:
- Superficial spreading melanoma: This type accounts for about 70% of all cases of melanoma. The most common locations are the legs of women and the backs of men, and they occur most commonly between the ages of 30-50. (Note: Melanomas can occur in other locations and at other ages, as well.) These melanomas are flat or barely raised and have a variety of colors. Such melanomas evolve over one to 5 years and can be readily caught at an early stage if they are detected and removed. An "in situ" melanoma (malignant melanoma in situ) refers to a very thin superficial spreading melanoma that does not extend beyond the junction of the dermis and epidermis, the normal location for melanocytes.
- Nodular melanoma: About 20% of melanomas are deeper, blue-black to purplish lumps. They may evolve faster and may also be more likely to spread. Untreated superficial spreading melanomas may become nodular and invasive.
- Lentigo maligna: Unlike other forms of melanoma, lentigo maligna tends to occur on places like the face, which are exposed to the sun constantly rather than intermittently. Lentigo maligna looks like a large, irregularly shaped or colored freckle and develops slowly. It may take many years to evolve into a more dangerous melanoma or may never become a more invasive form. Because of the unpredictability of future behavior, removal is recommended.
There are also other rarer forms of melanoma that may occur, for example, under the nails (subungual), on the palms and soles (acral lentiginous), uveal or choroidal (ocular), oral or other mucosal areas such as the vulva or penis, or sometimes even inside the body such as the brain.
What tests do health care professionals use to diagnose melanoma?
Most doctors diagnose melanoma by examining the spot causing concern and doing a biopsy. A skin biopsy refers to removing all or part of the skin spot under local anesthesia and sending the specimen to a pathologist for analysis. A small shave or punch biopsy which may be adequate for the diagnosis of other types of skin cancer is not the best for melanoma. To diagnose melanoma, the best biopsy is one that removes the entire extent of the visible tumor. Fine-needle aspiration may have a role in evaluating a swollen lymph node or a liver nodule but is not appropriate for the initial diagnosis of a suspicious skin lesion.
It is no longer recommended to do large batteries of screening tests on patients with thin, uncomplicated melanoma excisions, but patients who have had thicker tumors diagnosed or who already have signs and symptoms of metastatic melanoma may be recommended to have MRIs, PET scans, CT scans, chest X-rays, or other X-rays of bones when there is a concern of metastasis, blood tests of liver, and any other studies that will assist in staging (determining the extent of spread of the tumor).
The biopsy report may show any of the following:
- A totally benign condition requiring no further treatment, such as a regular mole
- An atypical mole which, depending on the judgment of the doctor and the pathologist, may need a conservative removal (taking off a little bit of normal skin all around just to make sure that the spot is completely out).
- A thin melanoma requiring surgery
- A thicker melanoma requires more extensive surgery or extra tests in which the lymph nodes are examined. Sentinel node biopsy is a procedure in which a dye or radioactive tracer is injected into the tumor site and then draining lymph nodes are identified and removed for microscopic examination. A negative result suggests there has not yet been spread through the lymphatic chain for that area of skin. A positive result suggests there may other lymph nodes involved. Since the removal of draining lymph node basins causes physical problems and does not seem to improve longevity it is no longer generally recommended.
Some doctors are skilled in a clinical technique called epiluminescence microscopy (also called dermatoscopy or dermoscopy). They may use a variety of instruments to evaluate the pigment and blood vessel pattern of a mole without having to remove it. Sometimes the findings support the diagnosis of possible melanoma, and at other times, the findings are reassuring that the spot is nothing to worry about. The standard for a conclusive diagnosis, however, remains a pathologic examination of a skin biopsy.
What are melanoma treatment options?
In general, early localized melanoma is treated by surgery alone. Doctors have learned that surgery does not need to be as extensive as was thought years ago. When treating many early melanomas, for instance, surgeons only remove 1 centimeter (less than ½ inch) of the normal tissue surrounding the melanoma. Deeper and more advanced cancers may need more extensive surgery.
Depending on various considerations (tumor thickness, body location, age, etc.), the removal of nearby lymph nodes may be recommended. For advanced disease, such as when the melanoma has spread to other parts of the body, treatments like immunotherapy or chemotherapy are sometimes recommended. Many of these treatments are still experimental and, for that reason, their use may be limited to patients willing to participate in a research study.
An Internet search will name a variety of home remedies and natural products for the treatment of skin cancers, including melanoma. These include the usual topical and systemic antioxidants and naturopathic immune stimulators. There is no scientific data supporting any of these, and their use may lead to unnecessary delay in better established treatments, possibly with tragic results.
How do doctors determine the staging and prognosis (outlook) of a melanoma?
The most useful criterion for determining prognosis is tumor thickness. Tumor thickness is measured in fractions of millimeters and is called the Breslow's depth. The thinner the melanoma, the better the prognosis. Any spread to lymph nodes or other body locations dramatically worsens the prognosis. Thin melanomas, those measuring less than 0.8 millimeters, have excellent cure rates, generally with local surgery alone. For thicker melanomas, the prognosis is guarded.
Melanoma is staged according to thickness, ulceration, lymph node involvement, and the presence of distant metastasis. The staging of a cancer refers to the extent to which it has spread at the time of diagnosis, and staging is used to determine the appropriate treatment. Stages 1 and 2 are confined to the skin only and are treated with surgical removal with the size of margins of normal skin to be removed determined by the thickness of the melanoma. Stage 3 refers to a melanoma that has spread locally or through the usual lymphatic drainage. Stage 4 refers to distant metastases to other organs, generally by spread through the bloodstream.
What is recurrent melanoma?
Recurrent melanoma refers to a recurrence of tumor at the site of removal of a previous tumor, such as in, around, or under the surgical scar. It may also refer to the appearance of metastatic melanoma in other body sites such as skin, lymph nodes, brain, or liver after the initial tumor has already been treated. Recurrence is most likely to occur within the first five years, but new tumors felt to be recurrences may show up decades later. Sometimes it is difficult to distinguish recurrences from new primary tumors.
What is metastatic melanoma?
Metastatic melanoma is melanoma that has spread beyond its original site in the skin to distant tissue sites. There are several types of metastatic melanoma. There may be spread through the lymphatic system to local lymph nodes. This may show up as swollen lymph glands (usually painless) or as a string of skin tumors along a lymphatic chain. Melanoma may also spread through the bloodstream (hematogenous spread), where it may appear in one or more distant sites, such as the lungs, liver, brain, remote skin locations, or any other body location.
What are the signs of symptoms of metastatic melanoma?
Signs and symptoms depend upon the site of metastasis and the amount of tumor there. Metastases to the brain may first appear as headaches, unusual numbness in the arms and legs, or seizures. Spread to the liver may be first identified by abnormal blood tests of liver function long before the patient has jaundice, a swollen liver, or any other signs of liver failure. Spread to the kidneys may cause pain and blood in the urine. Spread to the lungs may cause shortness of breath, other trouble breathing, chest pain, and continued cough. Spread to bones may cause bone pain or broken bones called pathologic fractures. A very high tumor burden may lead to fatigue, weight loss, weakness and, in rare cases, the release of so much melanin into the circulation that the patient may develop brown or black urine and have their skin turn a diffuse slate-gray color. The appearance of multiple blue-gray nodules (hard bumps) in the skin of a melanoma patient may indicate widespread melanoma metastases to remote skin sites.
What are the treatments for metastatic melanoma?
Historically, metastatic and recurrent melanoma have been poorly responsive to chemotherapy. Immunotherapy, in which the body's own immune system is energized to fight the tumor, has been a focus of research for decades. A variety of newer medications target different points in the pathways of melanoma cell growth and spread. While the most appropriate use of these medications is still being defined, the best treatment for melanoma remains complete surgical excision while it is still small, thin, and has not yet had a chance to spread.
Initial therapies to stimulate the immune system to help contain metastatic melanoma included infusions of interferon-alpha and interleukin-2 (both parts of the immune response to cancer and infection), and a few patients have responded to these therapies. There has, however, been an explosion recently in the approval of a number of targeted therapies that act on specific stages in the cell cycle, especially those of abnormal cells, and affect those growth processes of the tumor cells. Drugs that inhibit the kinase enzymes such as MEK, which is necessary for cell reproduction, include cobimetinib (Cotellic) and trametinib (Mekinist). Others target the signals for cell growth from abnormal BRAF genes and the enzymes they drive. Such medications in this family include dabrafenib (Tafinlar), vemurafenib (Zelboraf), and nivolumab (Opdivo). Pembrolizumab (Keytruda) blocks the tumor's ability to inhibit T cell activity. Ipilimumab (Yervoy) works directly on the T-lymphocyte pathway to activate the immune system. Many of these medications are now being used in combination to get better therapeutic effects than they would by themselves. All of these medications have significant side effects, including some that are life-threatening, and are indicated only for stage 3 tumors to try to prevent recurrence and spread and stage 4 metastatic tumors that are no longer amenable to surgery.
What are the survival rates for metastatic melanoma?
Survival rates for melanoma, especially for metastatic melanoma, vary widely according to many factors, including the patient's age, overall health, location of the tumor, particular findings on the examination of the biopsy, and of course the depth and stage of the tumor. Survival statistics are generally based on five-year survival rates rather than raw cure rates. Much of the success reported for the targeted therapies focuses on disease-free time because in many cases the actual five-year survival is not affected. It is hoped that combination therapy discussed above will change that.
- For stage 1 (thin melanoma, local only), five-year survival is ≥ 90%.
- For stage 2 (thicker melanoma, local only), five-year survival is 80%-90%.
- For stage 3 (local and nodal metastasis), five-year survival is around 50%.
- For stage 4 (distant metastasis), five-year survival is 10%-25% depending upon sex and other demographic factors.
What methods are available to help prevent melanoma?
- Reducing sun exposure: Avoidance of ultraviolet light exposure, including exposure in tanning booths, is the best means of helping to prevent melanoma, followed by wearing hats and opaque clothing, and then followed by broad-spectrum waterproof sunscreens applied liberally to exposed skin. The consensus among dermatologists is that sunscreens are helpful and are certainly preferable to unprotected sun exposure. (Despite sensational articles in the popular press, there is no credible evidence that sunscreens can cause melanoma. Data to indicate increased melanoma risk did not take into consideration that the sunscreens used by the subjects [at least as well as they could remember after decades] were far inferior to current products, which usually have much higher ultraviolet B SPF protection as well as ultraviolet A protection.)
- Early detection: Get one's skin checked at least once. Then, if it is recommended, have one's skin checked on a regular basis. The American Academy of Dermatology sponsors free skin cancer screening clinics every May all over the country. Special "Pigmented Lesion Clinics" have also been established in many medical centers to permit close clinical and photographic follow-up of patients at high risk.
- Screening of high-risk individuals: Anyone at high risk, such as anyone with a close relative who has melanoma, should be screened by a doctor for melanoma.
What research is being done on melanoma?
Research in melanoma is headed in three directions: prevention, more precise diagnosis, and better treatment for advanced disease.
- Prevention: Public education and more widely available screening clinics can increase public awareness of the need for sun avoidance, sunscreen use, and early detection of suspicious spots.
- More precise diagnosis: Newer experimental techniques, such as the confocal scanning laser microscope, may help doctors make more certain calls on borderline or suspicious spots without having to biopsy.
- Better treatment for advanced disease: Because conventional chemotherapy has been disappointing with melanoma, researchers have turned their attention to biologic treatments of advanced melanoma to stimulate the body's own immune response against the tumor. These new biologic treatments include immune checkpoint inhibitors, monoclonal antibodies, and drugs that target cell growth based on genetic changes in the melanoma. Many of these treatments are still investigational and intended for patients with widespread, recurrent life-threatening disease.
Where can people get more information about melanoma?
Health Solutions From Our Sponsors
Chae, Young Kwang, Michael S. Oh, and Francis J. Giles. "Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions." The Oncologist (2017): 1-12.
Mayer, J.E., S.M. Swetter, T. Fu, and A.C. Geller. "Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology." J Am Acad Dermatol 71.4 Oct. 2014: 599.e1-599.e12; quiz 610, 599.e12.
Mayer, J.E., S.M. Swetter, T. Fu, and A.C. Geller. "Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part II. Screening, education, and future directions." J Am Acad Dermatol 71.4 Oct. 2014: 611.e1-611.e10; quiz 621-2.
Schadendorf, Dirk, et al. "Melanoma." Nature Reviews: Disease Primers 1 (2015): 1-20.